Woei-Jer Chuang

This inventor holds 8 USPTO granted patents and 3 published patent applications, plus 2 CIPO patents and 2 EPO patents. Top assignees: National Cheng-Kung University, National Taiwan University, Dcb-USA LLC. Active years: 2011-2025.

USPTO Granted Patents = 8 (Patent Applications = 3)

% Patents Active = 62.5

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 2 (Patent Applications = 8)

Average Co-Inventor Count = 1.7

ph-index = 3

Forward Citations = 17(Granted Patents)

Company Filing History:

8 out of 653

National Cheng-Kung University

patents

4 out of 1,391

National Taiwan University

where one patent can have more than one assignee

Years Active: 2011-2025

Loading Chart...

8 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12338276 - Fibronectin type III domain-based protein and application thereof (2025-06-24),

2. 11202854 - Disintegrin variants and uses thereof (2021-12-21),

3. 10870684 - Disintegrin variants and pharmaceutical uses thereof (2020-12-22),

4. 10508137 - Disintegrin variants and pharmaceutical uses thereof (2019-12-17),

5. 9969791 - Modified fibronectin fragments or variants and uses thereof (2018-05-15),

6. 9044436 - Compositions and methods for the treatment of angiogenesis-related eye diseases (2015-06-02),

7. 8183201 - Methods of treating αvβ3 integrin-associated diseases by administering polypeptides selective for αvβ3 integrin (2012-05-22),

8. 7943728 - Disintegrin variants and their use in treating osteoporosis-induced bone loss and angiogenesis-related diseases (2011-05-17),

Title: Woei-Jer Chuang: Innovator in Protein Engineering

Introduction

Woei-Jer Chuang is a prominent inventor based in Tainan, Taiwan. He has made significant contributions to the field of protein engineering, holding a total of eight patents. His work focuses on innovative applications of proteins and disintegrin variants, which have important implications in medical technology.

Latest Patents

Among his latest patents is a groundbreaking invention related to a fibronectin type III domain-based protein. This invention provides a protein that includes a 10th human fibronectin type III domain, featuring specific mutations that allow for the formation of a disulfide bond. This advancement has potential applications in various biomedical fields. Another notable patent involves disintegrin variants, which are designed to suppress or inhibit platelet aggregation. This method can be particularly beneficial for patients suffering from conditions related to excessive platelet aggregation, and the disintegrin variant can be applied as a coating on implantable devices such as stents or catheters.

Career Highlights

Woei-Jer Chuang has had a distinguished career, working at esteemed institutions such as National Cheng Kung University and National Taiwan University. His academic and research endeavors have significantly advanced the understanding and application of protein engineering.

Collaborations

Throughout his career, Chuang has collaborated with notable colleagues, including Wen-Mei Fu and Tur-Fu Huang. These partnerships have fostered innovation and contributed to the success of his research projects.

Conclusion

Woei-Jer Chuang's contributions to protein engineering and his innovative patents highlight his role as a leading inventor in the field. His work continues to influence advancements in medical technology and improve patient outcomes.